I am delighted to introduce to you our coverage of this year’s ESMO World Congress of Gastro-Intestinal Cancer (WCGIC), which took place from 3-6 July in Barcelona. It was the 20th edition of this annual event, which has established itself as a premier educational forum, providing it’s 3500 attendees from 120 countries a comprehensive overview of state-of-the art diagnostics and features in the field of GI oncology.
Increasingly, the congress is also attracting investigators to present their study results and it should thus come at no surprise to you that Medicom launched it’s first WCGIC congress report this year. I am proud to count on an expert medical writer and contributions of a panel of expert reviewers for this edition.
Excitingly, there is truly practice changing news, also for still highly challenging cancers with increasing incidence but limited treatment options: a third-line treatment in gastric cancer, several systemic treatments for advanced hepatocellular cancers, and also new treatment options for bile cancers on the horizon.
Detecting recurrence early enough to provide efficient treatment including surgery is of major importance in colorectal cancer. Read about the utility liquid biopsies in this setting, implementation should be watched closely.
Treatment outcomes in mCRC cancer have made a great leap in the beginning of this century. If oncologists still hope to see a new “blockbuster” soon, we will still have to wait. The WCGIC comes with modest – still important - new data: clarifying options in third-line treatment and better identification of patients benefitting from triplet chemotherapies combined with biologicals in metastatic colorectal cancer are two examples.
I hope you will enjoy going through our report in detail
Yours sincerely,
Stefan Rauh
Posted on
Table of Contents: ESMO WCGIC 2018
Featured articles
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy